Pharmaceutical companies spend billions of dollars developing name-brand drugs, with the understanding that they will earn back that investment during the time they sell the drug under patent protection. But what happens when a generic drug manufacturer can provide a similar drug at a much lower cost, without infringing on the patent? If the generic [...]
The “patent cliff” is here, with patents on blockbuster drugs such as Singulair, Plavix, Seroquel and Actos expiring, and it is critical that pharmaceutical companies listen to what patients are saying about generic alternatives. Preconceptions and opinions about generic medications abound, but do patients have their facts straight? Analyzing thousands of patient discussions on health [...]
